TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 706

Group type: EXPERIMENTAL
Intervention: L-Dopa (900 mg + 225 mg benserazid daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: L-Dopa (600 mg + 150 mg benserazid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: L-Dopa (300 mg + 75 mg benserazid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30262209

Group type: EXPERIMENTAL
Intervention: EPAP therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 40
Study: 29100841

Group type: EXPERIMENTAL
Intervention: CHOICE for 3 months (n=100)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: CHOICEplus for 24 months (n=103)
Number of subjects: 203
Study: 27580832

Group type: EXPERIMENTAL
Intervention: Ethics officer intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparator RECs
Number of subjects: 24
Study: 24476776

Group type: EXPERIMENTAL
Intervention: Outdoor cycling
Number of subjects: 12

Group type: COMPARATOR
Intervention: Laboratory cycling
Number of subjects: 12
Study: 21036409

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 79873
Study: 20817013

Group type: EXPERIMENTAL
Intervention: 15 μg HA antigen dose
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Two 15 μg HA doses
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: 30 μg HA antigen dose
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Second dose of 30 μg HA antigen
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Vaccine overall
Number of subjects: 292
Study: 18399337

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg intravaginally every 6 hours, maximum of 4 doses)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oxytocin (maximum of 48 iu/min)
Number of subjects: 62
Study: 15707448

Group type: EXPERIMENTAL
Intervention: Turning group with a two-hour turning schedule
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Turning group with a four-hour turning schedule and pressure-reducing mattress
Number of subjects: 1772

Group type: COMPARATOR
Intervention: Non-turning group receiving preventive care based on clinical judgement
Number of subjects: 1772
Study: 12170269

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 251
Study: 10457872

Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg followed by 800 micrograms of misoprostol (phase 1)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Methotrexate 50 mg/m2 followed by 800 micrograms of misoprostol (phase 1)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg twice daily for 4 days followed by 800 micrograms of misoprostol (phase 2)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Methotrexate followed by 800 micrograms of misoprostol (phase 2)
Number of subjects: 398
Study: 8574913

Group type: EXPERIMENTAL
Intervention: Oesophageal manometry
Number of subjects: 36

Group type: COMPARATOR
Intervention: Clinical questionnaire on gastrointestinal symptoms
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: pH-metry
Number of subjects: 36
Study: 2467711

Group type: EXPERIMENTAL
Intervention: Iloprost intravenous infusions starting at 0.5 ng/kg/min and increased by 0.5 ng/kg/min every 15 minutes to a maximum of 2.0 ng/kg/min for eight hours on three consecutive days with a further single infusion at week 8.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nifedipine starting at 30 mg daily and increased to 60 mg daily after four weeks for another 12 weeks.
Number of subjects: 23
Study: 135163

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (2 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sulpirid (2.86 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31801993

Group type: EXPERIMENTAL
Intervention: Statin response (10% increase)
Number of subjects: 199122

Group type: EXPERIMENTAL
Intervention: Liability to T2D (doubling of odds)
Number of subjects: 199122
Study: 31175807

Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Usual-diet comparison group
Number of subjects: 48835
Study: 28238582

Group type: EXPERIMENTAL
Intervention: High-flexion knee prosthesis
Number of subjects: 960

Group type: COMPARATOR
Intervention: Standard posterior cruciate-substituting knee prosthesis
Number of subjects: 960
Study: 25197025

Group type: EXPERIMENTAL
Intervention: ISIS 325568 (400 mg/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23635996

Group type: EXPERIMENTAL
Intervention: MgSO4 30 mg kg(‐1) intravenously for 10 min, then continuous infusion at 1 g h(‐1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 64
Study: 21957896

Group type: EXPERIMENTAL
Intervention: Quinapril treatment for 3 months
Number of subjects: 54
Study: 19123333

Group type: EXPERIMENTAL
Intervention: Combined massage-smouldering-washing therapy (MSW)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mini-invasive surgery by arthroscopic mopping with sodium hyaluronate injection
Number of subjects: 60
Study: 16297965

Group type: EXPERIMENTAL
Intervention: Exposure to cement dust emissions
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Patch tests for sensitivity to cadmium
Number of subjects: 258

Group type: COMPARATOR
Intervention: Physical examination
Number of subjects: 258

Group type: COMPARATOR
Intervention: Soil and plant specimens analysis
Number of subjects: 258
Study: 12556921

Group type: EXPERIMENTAL
Intervention: High-frequency flow interruption
Number of subjects: 46

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 46
Study: 10843828

Group type: EXPERIMENTAL
Intervention: Mechanical aortic valve prosthesis
Number of subjects: 424
Study: 9354525

Group type: EXPERIMENTAL
Intervention: Epinephrine through the left atrial route
Number of subjects: 21

Group type: COMPARATOR
Intervention: Epinephrine through the central venous route
Number of subjects: 21
Study: 7693029

Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg rG‐CSF after induction therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg rG‐CSF after induction therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg rG‐CSF after consolidation therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg rG‐CSF after consolidation therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg rG‐CSF after consolidation therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: No rG‐CSF after consolidation therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Febrile neutropenia and incidence of documented infection in 5 and 10 micrograms/kg groups
Number of subjects: 41
Study: 3009635

Group type: EXPERIMENTAL
Intervention: Acyclovir given as prophylaxis against infection with herpes simplex virus
Number of subjects: 19

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Subclinical reactivation of VZV
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lymphocyte proliferation response to VZV antigen
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Herpes zoster
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Subclinical reactivation
Number of subjects: 19
Study: 29193314

Group type: EXPERIMENTAL
Intervention: Wobble board training
Number of subjects: 22
Study: 27144545

Group type: EXPERIMENTAL
Intervention: Bevacizumab with fluoropyrimidines (FP)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Surgery group (patients who underwent subsequent metastasectomy)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Non-surgery group
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: FP-O and FP-I regimens
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: FP-O and FP-I combined regimens
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Wild-type KRAS patients treated with anti-EGFR agent
Number of subjects: 753
Study: 25547618

Group type: EXPERIMENTAL
Intervention: Prosthesis on and finger marker on
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Prosthesis on and finger marker off
Number of subjects: 5

Group type: COMPARATOR
Intervention: Prosthesis off and finger marker on
Number of subjects: 5

Group type: COMPARATOR
Intervention: Prosthesis off and finger marker off
Number of subjects: 5
Study: 22956444

Group type: EXPERIMENTAL
Intervention: Intervention practices (received 6 months of intensive and 12 months of less intensive practice redesign support; 2 years of revised payment; 18 months of care management support)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control practices (received yearly participation payments plus cost of PPC(®)‐PCMH™)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 32
Study: 20538698

Group type: EXPERIMENTAL
Intervention: Childbirth during a 6-year follow-up in females
Number of subjects: 1786

Group type: COMPARATOR
Intervention: Control group (males)
Number of subjects: 1786
Study: 18795588

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 938

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg (for patients initially on RSV 10 mg who were uncontrolled)
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Switch from Atorvastatin 10 mg to Rosuvastatin 10 mg (for patients initially on ATV 10 mg who were uncontrolled)
Number of subjects: 938
Study: 16027027

Group type: EXPERIMENTAL
Intervention: Cervicogenic headache group
Number of subjects: 77

Group type: COMPARATOR
Intervention: Migraine with aura and control groups
Number of subjects: 77
Study: 15071261

Group type: EXPERIMENTAL
Intervention: TEE guided approach
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Conventional strategy (3 weeks of anticoagulation)
Number of subjects: 1222
Study: 11026125

Group type: EXPERIMENTAL
Intervention: Modified Therapeutic Community (TC)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 218
Study: 8599316

Group type: EXPERIMENTAL
Intervention: 1 g supplemental Ca/d as calcium carbonate (in lactating and nonlactating women)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lactating women after weaning
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lactating women who had resumed menses
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lactating women
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nonlactating women
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lactating women and nonlactating women
Number of subjects: 96
Study: 1732386

Group type: EXPERIMENTAL
Intervention: Clobetasol‐17‐propionate (CP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone‐17‐butyrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 3903546

Group type: EXPERIMENTAL
Intervention: Plasma exchange combined with prednisone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 25
Study: 30485409

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Physical activity orientation program
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combination of relaxation and physical activity
Number of subjects: 74
Study: 29587874

Group type: COMPARATOR
Intervention: SUR group (energy surplus with no exercise)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SUR + ARM group (energy surplus with vigorous-intensity arm crank ergometry)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SUR + MOD group (energy surplus with moderate-intensity treadmill walking)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SUR + BREAKS group (energy surplus with intermittent walking)
Number of subjects: 48
Study: 27193480

Group type: EXPERIMENTAL
Intervention: Two implant-supported overdentures
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Four implant-supported overdentures
Number of subjects: 52
Study: 25109416

Group type: EXPERIMENTAL
Intervention: Elpenhaler
Number of subjects: 100

Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 100
Study: 22520137

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV)
Number of subjects: 1308
Study: 20653227

Group type: EXPERIMENTAL
Intervention: Participants walking around a room
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants sitting at a desk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of background visual motion and relative movement of sound while sitting at a desk
Number of subjects: 0
Study: 18946061

Group type: EXPERIMENTAL
Intervention: Cetuximab plus best supportive care
Number of subjects: 394

Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 394
Study: 16210250

Group type: EXPERIMENTAL
Intervention: Point of care test for salivary nicotine metabolites
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no point of care test)
Number of subjects: 100
Study: 12226001

Group type: EXPERIMENTAL
Intervention: High consumption of fruits and vegetables (highest quintile)
Number of subjects: 27084

Group type: EXPERIMENTAL
Intervention: High lycopene intake (highest quintile)
Number of subjects: 27084

Group type: EXPERIMENTAL
Intervention: High lutein/zeaxanthin intake (highest quintile)
Number of subjects: 27084

Group type: EXPERIMENTAL
Intervention: High β‐cryptoxanthin intake (highest quintile)
Number of subjects: 27084

Group type: EXPERIMENTAL
Intervention: High total carotenoids intake (highest quintile)
Number of subjects: 27084

Group type: EXPERIMENTAL
Intervention: High serum β‐carotene levels
Number of subjects: 27084

Group type: EXPERIMENTAL
Intervention: High serum retinol levels
Number of subjects: 27084
Study: 11041405

Group type: EXPERIMENTAL
Intervention: Tinetti balance scale (cut-off score of 36 or less)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Screening positive with Tinetti balance scale
Number of subjects: 225
Study: 9214174

Group type: COMPARATOR
Intervention: Austin technique without lateral soft tissue release
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Austin technique with lateral soft tissue release
Number of subjects: 45
Study: 8417512

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (Hydralazine + Nitroglycerin)
Number of subjects: 0
Study: 2941277

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 100 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 250 mg (after breakfast)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 200 mg (20 min infusion)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (various doses)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (various doses)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 250 mg
Number of subjects: 32
Study: 30063750

Group type: EXPERIMENTAL
Intervention: Social interaction with robot that voiced an objection against being switched off
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Functional interaction with robot that voiced an objection against being switched off
Number of subjects: 85

Group type: COMPARATOR
Intervention: Functional interaction with robot that remained silent
Number of subjects: 85

Group type: COMPARATOR
Intervention: Social interaction with robot that remained silent
Number of subjects: 85
Study: 29901903

Group type: EXPERIMENTAL
Intervention: High dose MgSO4 (10 gm)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Low dose MgSO4 (5 gm)
Number of subjects: 88
Study: 24898851

Group type: EXPERIMENTAL
Intervention: Internal focus of attention (interoception)
Number of subjects: 48

Group type: COMPARATOR
Intervention: External focus of attention (exteroception)
Number of subjects: 48
Study: 22244408

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 110

Group type: COMPARATOR
Intervention: Patient-controlled analgesia
Number of subjects: 110
Study: 20145260

Group type: EXPERIMENTAL
Intervention: Over-encapsulated moxifloxacin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Over-encapsulated placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bare moxifloxacin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) moxifloxacin
Number of subjects: 22
Study: 18980516

Group type: EXPERIMENTAL
Intervention: Banded sites
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bonded sites
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 24
Study: 15735130

Group type: EXPERIMENTAL
Intervention: Health care provider-directed intervention
Number of subjects: 1978

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1978
Study: 12028871

Group type: EXPERIMENTAL
Intervention: Flexible coiled stainless steel stent (Freedom Force, Global Therapeutics)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Stiff tubular stainless steel stent (Crown, Johnson & Johnson)
Number of subjects: 44
Study: 10233122

Group type: EXPERIMENTAL
Intervention: Core temperature (Tc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin-surface temperature (Tsk)
Number of subjects: 0
Study: 8927272

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 348

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 348
Study: 1801570

Group type: EXPERIMENTAL
Intervention: Exposure to environmental cues
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exposure to negative affective cues
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ad libitum smoking
Number of subjects: 60
Study: 31003911

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus cobimetinib (840 mg intravenously every 2 weeks + 60 mg orally once daily for days 1–21 of a 28-day cycle)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy (1200 mg intravenously every 3 weeks)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Regorafenib (160 mg orally once daily for days 1–21 of a 28-day cycle)
Number of subjects: 363
Study: 28268201

Group type: EXPERIMENTAL
Intervention: Asset-based practices
Number of subjects: 71

Group type: COMPARATOR
Intervention: Needs-based practices
Number of subjects: 71
Study: 25830698

Group type: EXPERIMENTAL
Intervention: Initial PDT combined with IVR
Number of subjects: 72

Group type: COMPARATOR
Intervention: Later PDT combined with IVR
Number of subjects: 72
Study: 23859672

Group type: EXPERIMENTAL
Intervention: 2 g of cefazolin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 g of cefazolin
Number of subjects: 20
Study: 21867378

Group type: EXPERIMENTAL
Intervention: Hypnosis (H)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Hypnosis (NH)
Number of subjects: 30
Study: 19390749

Group type: EXPERIMENTAL
Intervention: Recognition of forms (rf) test
Number of subjects: 50

Group type: COMPARATOR
Intervention: Assessment by speech and language therapists (SLT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rf-test (test-retest)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rf-test performance
Number of subjects: 50
Study: 17721966

Group type: EXPERIMENTAL
Intervention: TRiM training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal military support networks
Number of subjects: 0

Group type: COMPARATOR
Intervention: General health
Number of subjects: 0
Study: 15088127

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous interleukin 2 (IL-2) and interferon alpha (IFN-alpha) alone (n = 23)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous interleukin 2 (IL-2) and interferon alpha (IFN-alpha) in combination with histamine dihydrochloride (n = 26)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cytokine therapy (IL-2 and IFN-alpha)
Number of subjects: 49
Study: 11418230

Group type: EXPERIMENTAL
Intervention: Citalopram treatment (for those with high PRL response)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Citalopram treatment (for those with low PRL response)
Number of subjects: 17
Study: 9876958

Group type: EXPERIMENTAL
Intervention: 75 mg xanomeline tartrate three times daily (t.i.d.)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: ADAS-cog
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: CNTB
Number of subjects: 343
Study: 7976162

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.6 mg kg‐1 during balanced anesthesia (nitrous oxide and fentanyl)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.6 mg kg‐1 during halothane anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.9 mg kg‐1 during balanced anesthesia (nitrous oxide and fentanyl)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.9 mg kg‐1 during halothane anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.9 mg kg‐1 during anesthesia with nitrous oxide, oxygen, and isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 2514694

Group type: EXPERIMENTAL
Intervention: Glycolande N (modified glibenclamide formulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Marketed standard preparation (glibenclamide)
Number of subjects: 12
Study: 1104076

Group type: EXPERIMENTAL
Intervention: Oxytetracycline (Imperacin-I.C.I.)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Tetrabid-Organon (sustained-release tetracycline hydrochloride)
Number of subjects: 259
Study: 30814028

Group type: EXPERIMENTAL
Intervention: lopinavir–ritonavir
Number of subjects: 1266

Group type: COMPARATOR
Intervention: lamivudine
Number of subjects: 1266
Study: 27876790

Group type: EXPERIMENTAL
Intervention: MR-antagonist spironolactone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Stress induction with cortisol increase
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 101